Startseite Endometriosis and the menopause: why the question merits our full attention
Artikel
Lizenziert
Nicht lizenziert Erfordert eine Authentifizierung

Endometriosis and the menopause: why the question merits our full attention

  • Lydia Marie-Scemama EMAIL logo , Marc Even , Jean Bouquet De La Joliniere und Jean-Marc Ayoubi
Veröffentlicht/Copyright: 26. März 2019
Veröffentlichen auch Sie bei De Gruyter Brill

Abstract

As an estrogen-dependent disease, endometriosis was thought to become less active or regress with the onset of the menopause. However, based on some new data, we are discovering that this pathology can emerge or reappear at this period of life. Clinicians must consider it as a possible cause for cases of pelvic pain, and heavy bleeding. Authors have described a possibility of transformation of the intraperitoneal proliferation into a malignant type with ovarian, bowel and even lung metastasis. The risk of transformation into an ovarian cancer is around 2 or 3%. The role of menopausal hormonal therapy will be discussed as in recurrence in the case of residue existence, especially after incomplete surgery. Is it possible to prescribe hormonal therapy to a menopausal women suffering climacteric symptoms as it could trigger a recurrence of endometriosis and even an increased risk of malignant degeneration? This remains unclear. It is an unresolved therapeutic dilemma; the choice between surgery or medical treatment?

References

[1] Sampson JA. Metastatic or embolic endometriosis due to premenstrual dissemination of endometrial tissue into the peritoneal cavity. Am J Obstet Gynecol. 1927;3:93–110.Suche in Google Scholar

[2] Vercellini P, Vigano P, Somigliana E, Fedele L. Endometriosis: pathogenesis and treatment. Nat Rev Endocrinol. 2014;10:261–75.10.1038/nrendo.2013.255Suche in Google Scholar PubMed

[3] Burney RO, Talbi S, Hamilton AE, Vo KC, Nezhat CR, Lessey BA, et al. Gene expression analysis of endometrium reveals progesterone resistance and candidate susceptibility genes in women with endometriosis. Endocrinology. 2007;148:3814–26.10.1210/en.2006-1692Suche in Google Scholar PubMed

[4] Santulli P, Borghese B, Noel JC, Fayt I, Anaf V, de Ziegler D, et al. Hormonotherapy deregulates prostaglandin-endoperoxidase synthase (PTGS2) expression in endometriotic tissues. J Clin Endocrinol Metab. 2014;99:881–90.10.1210/jc.2013-2950Suche in Google Scholar PubMed

[5] Santulli P, Chouzenoux S, Fiorese M, Marcellin L, Lemarechal H, Millischer AE, et al. Protein oxidative stress markers in peritoneal fluids of women with deep infiltrating endometriosis are increased. Hum Reprod. 2015;30:49–60.10.1093/humrep/deu290Suche in Google Scholar PubMed

[6] Leconte M, Nicco C, Ngo C, Chereau C, Chouzenoux S, Marut W, et al. The mTOR/AKT inhibitor temsirolimus prevents deep infiltrating endometriosis in mice. Am J Pathol. 2011;179:880–9.10.1016/j.ajpath.2011.04.020Suche in Google Scholar PubMed PubMed Central

[7] Ngo C, Nicco C, Leconte M, Chereau C, Arkwright S, VAcher Lavenu MC, et al. Protein kinase inhibitors can control the progression of endometriosis in vitro and in vivo. J Pathol. 2010;222:148–57.10.1002/path.2756Suche in Google Scholar PubMed

[8] Borghese B, Tost J, de Surville M, Busato F, Letourneur F, Mondon F, et al. Identification of susceptibility genes for peritoneal, ovarian, and deep infiltrating endometriosis using a pool sample-based genome-wide association study. Biomed Res Int. 2015;2015:461024.10.1155/2015/461024Suche in Google Scholar PubMed PubMed Central

[9] Nyholt DR, Low SK, Anderson CA, Painter JN, Uno S, Morris AP, et al. Genome-wide association meta-analysis identifies new endometriosis risk loci. Nat Genet. 2012;44:1355–9.10.1038/ng.2445Suche in Google Scholar PubMed PubMed Central

[10] Pagliardini L, Gentilini D, Vigano P, Panina-Bordignon P, Busacca M, Candiani M, et al. An Italian association study and meta-analysis with previous GWAS confirm WNT4, CDKN2BAS and FN1 as the first identified susceptibility loci for endometriosis. J Med Genet. 2013;50:43–6.10.1136/jmedgenet-2012-101257Suche in Google Scholar PubMed

[11] Borghese B, Barbaux S, Mondon F, Santulli P, Pierre G, Vinci G, et al. Research resource: genome wide profiling of methylated promoters in endometriosis. Mol Endocrinol. 2010;24:1872–85.10.1210/me.2010-0160Suche in Google Scholar PubMed PubMed Central

[12] Umezawa M, Sakata C, Tanaka N, Tabata M, Takeda K, Ihara T, et al. Pathological study for the effects of in utero and postnatal exposure to diesel exhaust on a rat endometriosis model. J Toxicol Sci. 2011;36:493–8.10.2131/jts.36.493Suche in Google Scholar

[13] Bendon CL, Becker CM. Potential mechanisms of postmenopausal endometriosis. Maturitas. 2012;72:214–19.10.1016/j.maturitas.2012.04.010Suche in Google Scholar

[14] Bulun SE. Endometriosis. N Engl J Med. 2009;360:268–79.10.1016/B978-0-323-47912-7.00025-1Suche in Google Scholar

[15] Bulun SE, Yang S, Fang Z, Gurates B, Tamura M, Sebastian S. Estrogen production and metabolism in endometriosis. Ann N Y Acad Sci. 2002;955:396–406.10.1111/j.1749-6632.2002.tb02767.xSuche in Google Scholar

[16] Tan DA, Almaria MJ. Postmenopausal endometriosis: drawing a clearer clinical picture. Climateric. 2018;21:249–55.10.1080/13697137.2018.1450855Suche in Google Scholar

[17] Haas D, Chvatal R, Reichert B, Rennert S, Shebl O, Binder H, et al. Endometriosis: a premenopausal disease? Arch Gynecol Obstet. 2012;286:667–70.10.1007/s00404-012-2361-zSuche in Google Scholar

[18] Gemmell LC, Webster KE, Kirtley S, Vincent K, Zondervan KT, Becker CM. The management of menopause in women with a history of endometriosis: a systematic review. Human Reprod Update. 2017;23:481–500.10.1093/humupd/dmx011Suche in Google Scholar

[19] Soliman NF, Hillard TC. Hormone replacement herapy in women with past history of endometriosis. Climateric. 2006;9:325–35.10.1080/13697130600868711Suche in Google Scholar

[20] Al Kadri H, Hassan S, Al-Fozan HM, Hajeer A. Hormone therapy for endometriosis and surgical menopause. Cochrane Database Syst Rev. 2009. DOI: 10.1002/14651858.CD005997.pub2.Suche in Google Scholar

[21] Fedele L, Bianchi S, Raffaelli R, Zanconato G. Comparison of transdermal estradiol and tibolone for the treatment of oophorectomized women with deep residual endometriosis. Fert Steril. 1989;51:781–5.10.1016/S0378-5122(99)00032-8Suche in Google Scholar

[22] Moen MH, Rees M, Brincat M, Erel T, Gambacciani M, Lambrinoudaki I, et al. European Menopause and Andropause Society. EMAS position statement: managing the menopause in women with a past history of endometriosis. Maturitas. 2010;67:94–7.10.1016/j.maturitas.2010.04.018Suche in Google Scholar PubMed

[23] Stern RC, Dash R, Bentley RC, Snyder MJ, Haney AF, Robboy SJ. Malignancy in endometriosis: frequency and comparison of ovarian and extraovarian types. Int J Gynecol Pathol. 2001;20:133–9.10.1097/00004347-200104000-00004Suche in Google Scholar PubMed

[24] Melin A, Sparen P, Perrson I, Bergqvist A. Endometriosis and the risk of cancer with special emphasis on ovarian cancer. Human Reprod. 2006;21:1237–42.10.1093/humrep/dei462Suche in Google Scholar PubMed

[25] Audebert A. Women with endometriosis: are they different from others? Gynecol Obstet Fertil. 2005;33:239–46.10.1016/j.gyobfe.2005.03.010Suche in Google Scholar PubMed

[26] Chene G. Is endometriosis a pre-cancerous lesion Perspectives Implications Cliniques. Gynécol Obstét Fertilité 2016.10.1016/j.gyobfe.2016.01.001Suche in Google Scholar PubMed

[27] Inceboz U. Endometriosis after menopause. Womens Health (Lond). 2015;11:711–15.10.2217/whe.15.59Suche in Google Scholar PubMed

[28] Streuli I, Gaitzch H, Wenger JM, Petignat P. Endometriosis after menopause: physiopathology and management of an uncommon condition. Climateric. 2017;20:138–43.10.1080/13697137.2017.1284781Suche in Google Scholar PubMed

[29] Polyzos NP, Fatemi HM, Zavos A, Papanikolau EG. Aromatase inhibitors in post menopausal endometriosis. Reprod Biol Endocrinol. 2011;9:90.10.1186/1477-7827-9-90Suche in Google Scholar PubMed PubMed Central

Received: 2018-10-20
Accepted: 2019-01-20
Published Online: 2019-03-26

©2019 Walter de Gruyter GmbH, Berlin/Boston

Heruntergeladen am 30.10.2025 von https://www.degruyterbrill.com/document/doi/10.1515/hmbci-2018-0071/html
Button zum nach oben scrollen